Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01369953 · ClinicalTrials.gov registry record

Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants

A clinical trial of Coronary Artery Disease and Proteus Syndrome, sponsored by National Human Genome Research Institute (NHGRI).

Completed
Registry status
30
Enrollment target
1
Study location

NCT01369953: Completed study of Coronary Artery Disease and Proteus Syndrome, sponsored by National Human Genome Research Institute (NHGRI).

NCT01369953 is a study of Coronary Artery Disease and Proteus Syndrome that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 30 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01369953, a study of Coronary Artery Disease and Proteus Syndrome, has completed, sponsored by National Human Genome Research Institute (NHGRI).

COMPLETED
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

Since 2007, the cost of sequencing a diploid human genome has fallen dramatically, from approximately $70 million to $20,000. As affordable sequencing platforms become more widely available, the advancement of biomedical science will draw increasingly on whole genome sequencing research requiring large cohorts of diverse populations. Key policy, ethical and legal implications of these developments will need to be understood in order to promote the efficacy and effectiveness of genomic research going forward. An overall aim of this project is to obtain feedback on the informed consent process from some of the earliest particpants in studies using whole genome sequencing. A more specific goal is to characterize the salient personal and public references accessed by participants around the time of the informed consent process. By highlighting trends in participants views about study participation around the time of the initial informed consent process, we aim to advance the development of an ethically and socially relevant vocabulary with which to negotiate future terms of use for personal sequence data in genomic research. Participants will be asked to complete a one-time, semi-structured telephone interview lasting approximately 45 minutes in the period 2-8 weeks following their initial informed consent session at the NIH. They will be recruited from two NIH protocols employing whole genome sequencing for distinct purposes. They The ClinSeqTM Study is a large-scale medical sequencing project investigating the causal role of genetics in cardiovascular disease enrolling both symptomatic and healthy individuals. The Whole Genome Medical Sequencing for Gene Discovery Study (WGMS) enrolls children and adults for full sequencing with the aim of discovering the genetic etiology of rare conditions.

Study Locations (1)

Maryland

  • National Human Genome Research Institute (NHGRI), 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-05-29
Est. Completion 2014-01-31

What the finished NCT01369953 record still lists

NCT01369953 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower).

The record links to 5 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01369953 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01369953 about?

NCT01369953 is a clinical study titled "Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants". Since 2007, the cost of sequencing a diploid human genome has fallen dramatically, from approximately $70 million to $20,000. As affordable sequencing platforms become more widely available, the advancement of biomedical science will draw increasingly on whole genome sequencing research requiring la...

What is the current status of trial NCT01369953?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2011-05-29. Estimated completion is 2014-01-31.

What conditions does trial NCT01369953 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Proteus Syndrome, Coffin - Sins Syndrome, Familial Isolated Hyperparathyroidism, Dubouitz Syndrome.

Who is sponsoring clinical trial NCT01369953?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01369953 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01369953's enrollment target sits among peer trials

30 198th of 219 higher than 17 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01369953, the US trial registry maintained by the National Library of Medicine. NCT01369953 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.